trending Market Intelligence /marketintelligence/en/news-insights/trending/on7UVhf2yPQugL6W36ARMQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aptose Biosciences closes $74.2M common stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Aptose Biosciences closes $74.2M common stock offering

Aptose Biosciences Inc. closed its offering of 18,543,750 common shares priced at $4 per share.

The number of shares sold includes the full exercise of underwriters of their option to buy additional shares.

Gross proceeds were about $74.2 million.

Piper Jaffray & Co. acted as sole active book-running manager for the offering, while Canaccord Genuity acted as passive book-running manager. Oppenheimer & Co. was lead manager, while JonesTrading Institutional Services LLC was co-manager for the offer.

Toronto-based Aptose Biosciences develops personalized therapies for cancer in the U.S. Its drug candidate APTO-253 is in a phase 1b clinical trial for treating patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome.